Bayer’s CRISPR venture opens for business in biotech hub
August 23, 2016Manufacturing and Production, Research and Development Bayer, casebia, crispr, gene editing, gene-editing
Bayer and CRISPR Therapeutics have joined together to launch Casebia Therapeutics and have chosen Cambridge, Massachusetts, as its base to …
Gilead gets EU approval for HIV-prevention treatment Truvada
August 23, 2016Manufacturing and Production, Sales and Marketing EU, Gilead, HIV, PrEP, Truvada, prevention
Gilead Sciences has received marketing authorisation from the European Commission for once-daily Truvada (emtricitabine/tenofovir disoproxil), in combination with safer sex …
Valeant appoints new executive VP of finance and CFO
August 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Valeant, appointment
Valeant has announced the appointment of Paul S. Herendeen as executive vice president, who will also take over as chief …
FDA fast tracks Alzheimer’s drug from Lilly, AstraZeneca
August 22, 2016Manufacturing and Production, Research and Development Alzheimer's disease, AstraZeneca, BACE, lilly, phase III
AstraZeneca and Eli Lilly have announced that the US Food and Drug Administration (FDA) has granted AZD3293 its fast track …
Doctors receiving drugmaker payments more likely to prescribe their products, BMJ study finds
August 22, 2016Research and Development, Sales and Marketing
US physicians who received gifts and other payments from drug companies were more likely to prescribe branded anticoagulants and diabetes …
MHRA suspends GMP certificate for Pfizer site in India
August 22, 2016Manufacturing and Production, Sales and Marketing GMP, India, MHRA, Pfizer, ban, facility, import, suspend
The UK’s Medicines and Healthcare Products Agency (MHRA) has recommended that an Indian facility belonging to Pfizer’s Hospira unit be …
FDA delays appraisal of Sanofi, Zealand diabetes drug just days before decision due
August 22, 2016Research and Development, Sales and Marketing NDA, Sanofi, appraisal, diabetes, iglarlixi, type 2, type-2, zealand
There was unfortunate news for Sanofi and Zealand Pharma as the FDA announced that it required additional information, constituting a …
Pfizer acquires Medivation for $14 billion
August 22, 2016Sales and Marketing Medivation, Pfizer, acquisition, oncology
Pfizer has sealed the deal to acquire US cancer drug company Medivation for close to $14 billion in a move …
FDA approves Pfizer’s abuse-deterrent opioid painkiller
August 22, 2016Sales and Marketing FDA, Pfizer, abuse deterrent, abuse-deterrent, approval, opioid, troxyca
Pfizer has announced that the US FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for the …
Top ten stories in the pharmaceutical industry this week
August 19, 2016Medical Communications pharmafile, top ten
The end of another week, and from huge expansions and investments to some shocking and saddening tragedies, it’s been a …
EU grants marketing authorisation for Teva’s asthma drug Cinqaero
August 19, 2016Medical Communications, Sales and Marketing EU, Teva, approval, asthma, cinqaero, eosinophilic
The European Commission has granted marketing authorisation for Teva’s Cinqaero (reslizumab), as an odd-on therapy in adult patients with severe …
Bayer’s liver cancer drug not cost-effective, says NICE
August 19, 2016Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer
NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …
Former shareholders sue Valeant, alleging “vast fraud”
August 19, 2016Medical Communications, Sales and Marketing Valeant, fraud, lawsuit, t rowe price
Valeant Pharmaceuticals has confirmed that it is being sued by one its former largest shareholders, T Rowe Price, who claim …
Intercept’s Ocaliva meets primary endpoint in Phase III trial for rare liver disease
August 18, 2016Medical Communications, Research and Development intercept, ocaliva
Intercept Pharmaceuticals have announced the publication of Phase III results published in the New England Journal of Medicine, where Ocaliva …
Chinese investors plan $1 billion US biotech site
August 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
China’s state-backed developer Greenland Holdings is set to jointly invested over $1 billion in a San Francisco-based biotech industrial park …
J&J loses Remicade patent fight, pledges to continue fight against biosimilars
August 18, 2016Research and Development, Sales and Marketing Johnson and Johnson, Remicade, biosimilar, biosimilars, infliximab, patent
Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …
Pfizer’s Xalkori price drop secures NICE recommendation
August 18, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer
The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …
MSD joins Medivation race, says reports
August 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover
MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …
NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund
August 18, 2016Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica
NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …
Untested cancer drug suspected cause of three deaths at German alternative medicine centre
August 17, 2016Research and Development 3-Bromopyruvate, Cancer, Germany, alternative medicine, patient deaths
The deaths of three patients at an alternative medicine clinic in Germany have prompted suspicion of a clinically untested cancer …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
